Recombinant vaccine for canine parvovirus in dogs.

AUTOR(ES)

López de Turiso, J A

RESUMO

VP2 is the major component of canine parvovirus (CPV) capsids. The VP2-coding gene was engineered to be expressed by a recombinant baculovirus under the control of the polyhedrin promoter. A transfer vector that contains the lacZ gene under the control of the p10 promoter was used in order to facilitate the selection of recombinants. The expressed VP2 was found to be structurally and immunologically indistinguishable from authentic VP2. The recombinant VP2 shows also the capability to self-assemble, forming viruslike particles similar in size and appearance to CPV virions. These viruslike particles have been used to immunize dogs in different doses and combinations of adjuvants, and the anti-CPV responses have been measured by enzyme-linked immunosorbent assay, monolayer protection assays, and an assay for the inhibition of hemagglutination. A dose of ca. 10 micrograms of VP2 was able to elicit a good protective response, higher than that obtained with a commercially available, inactivated vaccine. The results indicate that these viruslike particles can be used to protect dogs from CPV infection.

Documentos Relacionados

• First peptide vaccine providing protection against viral infection in the target animal: studies of canine parvovirus in dogs.
• Comparison of systemic and local immunity in dogs with canine parvovirus gastroenteritis.
• Iontophoresis for modulation of cardiac drug delivery in dogs.
• Virologic and Serologic Identification of Minute Virus of Canines (Canine Parvovirus Type 1) from Dogs in Japan
• Tuberculin-specific transfer factor in dogs.